Wendy R. Parulekar

Also affiliated with Canadian Cancer Trials Group

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).”.

Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.526

N/A

0DataRank · unranked

0 citations

Bingshu E. Chen, Wendy R. Parulekar, Julie Lemieux, Jennifer A. Ligibel, Karen A. Gelmon +3 more

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

The Lancet(2023)10.1016/s0140-6736(23)00285-4

N/A

0DataRank · unranked

195 citations

Rosie Bradley, Richard Gray, Robert K. Hills, Hongchao Pan, Richárd Pető +95 more